A Moroccan research foundation has developed the first cancer diagnostic tests ever made on African soil — a milestone that could cut both the cost and the waiting time for breast cancer and leukemia diagnosis across the continent.
At a glance
- Cancer diagnostics: The Moroccan Foundation for Advanced Science, Innovation and Research (MASciR) developed the new tests for breast cancer and leukemia, making Morocco the first African country to produce cancer diagnostic kits domestically.
- Leukemia test: MASciR’s leukemia test had already been used on 400 patients at the time of its launch and can return results in a matter of hours rather than the weeks or months that imported kits can require.
- African healthcare access: The tests are expected to become available first in Francophone nations including Tunisia, Senegal, Ivory Coast, and Rwanda — countries where MASciR already has a track record, having sold its African-developed COVID-19 test there earlier.
Why imported kits are such a barrier
Across most of Africa, hospitals rely almost entirely on diagnostic kits imported from Europe or North America. That dependence carries two costs that routinely delay or deny care: price and time.
“The price of the kit can be double that of what it would cost to manufacture it locally. It is also a long process. It can take weeks or months for the kits to arrive,” said Hassan Sefrioui, an executive board member of MASciR, the Rabat-based foundation that developed the tests.
For some cancers, the problem runs even deeper. Results from certain imported diagnostic tests used in Morocco had previously needed to be sent back to France for interpretation — adding yet another layer of delay for patients who may already be at an advanced stage by the time they seek care.
What this means for Morocco specifically
Breast cancer is the most prevalent form of cancer in Morocco and a leading cause of death among women in the country. Having a domestically produced test removes a structural obstacle that has long slowed early detection and treatment.
Early detection is the single most powerful tool in cancer survival rates. A test that returns results in hours — rather than weeks — means clinicians can act sooner, and patients face a less harrowing wait.
MASciR is not a newcomer to high-stakes diagnostics. The foundation was among the first institutions in Africa to develop a COVID-19 test, which was subsequently distributed across Francophone Africa. That prior experience gives the cancer tests a ready distribution network from the outset.
A model for African medical self-sufficiency
The broader significance of Morocco’s achievement sits within a long-running debate about Africa’s dependence on imported medical supplies. The COVID-19 pandemic exposed just how fragile that dependence was, with global supply chains seizing up precisely when demand for diagnostics and treatments was highest.
Building local manufacturing capacity — for diagnostics, medicines, and eventually vaccines — is now a stated priority for bodies including the Africa Centres for Disease Control and Prevention and the African Union. Morocco’s cancer tests are a concrete step in that direction.
Officials at the African Pharmaceutical Technology Foundation have said that if MASciR receives strong institutional support, costs could come down quickly and significantly, potentially making the tests cheaper than their European equivalents over time.
The honest limitations
The path to affordability is not immediate. Because raw materials for the tests still need to be imported, the kits are likely to cost more than European-made alternatives for at least the first several years of production. Widespread adoption across the continent will depend on sustained funding, regulatory approvals in each target country, and the kind of long-term institutional backing that has not always materialized for African health innovation.
Still, the existence of the test matters in itself. A continent that can diagnose its own cancers — without waiting for a shipment from across the ocean — is a continent better equipped to save its own people. Morocco has shown it can be done. The question now is whether the investment follows to scale it.
The MASciR foundation has positioned itself as a model for what publicly supported African research institutions can achieve when given the resources to compete at a global level. Its work on both COVID-19 and cancer diagnostics suggests that the infrastructure for local diagnostic manufacturing in Africa is not a distant aspiration — it is already under construction.
Read more
For more on this story, see: Good News Network
For more from Good News for Humankind, see:
- U.K. cancer death rates fall to their lowest level on record
- Marie-Louise Eta becomes the first female head coach in men’s top-flight European football
- The Good News for Humankind archive on Morocco
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
